DNA

#2377
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
9.5 6 USD
+2.47%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
9.50
9.75
1年のレンジ
5.37
10.64
1日の変化
+2.47%
月次変化
+27.21%
6か月変化
+7.66%
1年の変化
+7.66%
以前の終値
9.3 3
Open
9.5 9
安値
9.5 0
High
9.7 5
ボリューム
204
チャート全体を表示 Full chart

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 595.82 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-1.47
売上高対価格比率
2.71

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

ニュース